A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine

Cephalalgia

Volumn 24, Issue 10, 2004, Pages 875-882

  Tvedskov, Jesper Filtenborg ^a   Iversen, H K ^a   Olesen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Drug interaction; Experimental; Glyceryltrinitrate; Headache; Human; Hypotension; Migraine; Neurological model; Nitric oxide; Nitroglycerin; Pharmacology; SB 220453; Tonerbasat

Indexed keywords

BENZOPYRAN DERIVATIVE; GLYCERYL TRINITRATE; TONABERSAT;

ADULT; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAND MAL EPILEPSY; HEADACHE; HUMAN; HYPOTENSION; MALE; MIGRAINE; NEUROGENIC INFLAMMATION; RANDOMIZED CONTROLLED TRIAL; TRIGEMINAL NERVE; VASODILATATION;

ADULT; BENZAMIDES; BENZOPYRANS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NITROGLYCERIN; STATISTICS, NONPARAMETRIC;

EID: 4844226579     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00762.x     Document Type: Article

References (15)

1. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1994; 1:73-80.
2. Iversen HK. Experimental headache in humans. Cephalalgia 1995; 15:281-7.
3. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol 1996; 49:335-9.
4. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16:412-8.
5. Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 2004; 24:576-85.
6. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA et al. Identification of (-)-cis-6-acetyl-4S-3-chloro-4-fluoro-benzoylamino-3,4- dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett 1999; 9:285-90.
7. Smith MI, Read SJ, Chan WN, Thompson M, Hunter AJ, Upton N et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000; 20:546-53.
8. Parsons AA, Bingham S, Raval P, Read S, Thompson M, Upton N. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol 2001; 132:1549-57.
9. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 2000; 20:92-9.
10. SmithKlineBeeecham. Investigator Brochure SB-22453, edition 2. 1998.
11. MaassenVanDenBrink A, van den Broek RW, de Vries R, Upton N, Parsons AA, Saxena PR. The potential antimigraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 2000; 20:538-45.
12. Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003; 60:935-40.
13. Cady RK, Sheftell F, Lipton RB, O'Quinn S, Pharm D, Jones M et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22:1035-48.
14. Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001; 85:959-70.
15. Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 2001; 15:583-7.